Skip to main content

Real-world experience of secukinumab treatment for ankylosing spondylitis at the Royal National Hospital for Rheumatic Diseases, Bath


We reviewed our experience of treating ankylosing spondylitis patients with the IL-17 inhibitor secukinumab at the Royal National Hospital for Rheumatic Diseases, Bath. A total of 76 patients were included, of whom secukinumab was the first-line biologic drug used in 24, second line in 23, and third line in 29 patients, respectively. Only 5 patients discontinued the drug due to side effects before their first outpatient review, including 1 new case of inflammatory bowel disease. Significant improvements were seen in all disease outcome measures in patients receiving secukinumab as their first-line biologic agent, with a trend to improved mean BASDAI and BASFI even in patients receiving it as a second- or third-line biologic agent. This real-world analysis adds to the evidence recommending secukinumab as a largely safe and effective treatment for ankylosing spondylitis.

Key Points

Secukinumab was efficacious for improving short-term mean disease activity and function in our cohort of ankylosing spondylitis patients, regardless of whether used as the first-, second-, or third-line biologic disease-modifying drug.

There were very low rates of discontinuation due to side effects in our cohort of secukinumab-treated ankylosing spondylitis patients.

This is a preview of subscription content, access via your institution.


  1. Ramiro S, van der Heijde D, van Tubergen A, Stolwijk C, Dougados M, van den Bosch F, Landewé R (2014) Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort. Ann Rheum Dis 73:1455–1461

    Article  Google Scholar 

  2. Poddubnyy D, Protopopov M, Haibel H, Braun J, Rudwaleit M, Sieper J (2016) High disease activity according to the Ankylosing Spondylitis Disease Activity Score is associated with accelerated radiographic spinal progression in patients with early axial spondyloarthritis: results from the GErman SPondyloarthritis Inception Cohort. Ann Rheum Dis 75:2114–2118

    Article  Google Scholar 

  3. Baeten D, Baraliakos X, Braun J et al (2013) Anti-interleukin-17A monoclonal antibody secukinumab in the treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet 382:1705–1713

    Article  CAS  Google Scholar 

  4. NICE TA407 2016: secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors

Download references


Dr. Raj Sengupta would like to acknowledge his grants from Abbvie, Biogen, Novartis, Celgene, and UCB.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Thomas Williams.

Ethics declarations




All data reported in this article was obtained from routine clinical practice. Patients included have all provided informed consent to enter the BathSpA biobank database for the purpose of research studies.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Williams, T., Wadeley, A., Bond, D. et al. Real-world experience of secukinumab treatment for ankylosing spondylitis at the Royal National Hospital for Rheumatic Diseases, Bath. Clin Rheumatol 39, 1501–1504 (2020).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


  • Ankylosing spondylitis
  • Biologic disease-modifying drug
  • Secukinumab